ReviewTrends in molecular medicine2011
NKT cell costimulation: experimental progress and therapeutic promise.
Review in Trends in molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 62 citations in OpenAlex.
- Trial
- Classic costimulatory interactions in MAIT cell responses: from gene expression to immune regulation.Clinical and experimental immunology · 2023Article
- Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens.PLoS pathogens · 2023Article
- Review
- Chronic stress physically spares but functionally impairs innate-like invariant T cells.Cell reports · 2021Article
- Measles Virus Infects and Programs MAIT Cells for Apoptosis.The Journal of infectious diseases · 2021Article
- Harnessing the Versatility of Invariant NKT Cells in a Stepwise Approach to Sepsis Immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- In Vivo Cytotoxicity by α-GalCer-transactivated NK Cells.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Leveraging Public Single-Cell and Bulk Transcriptomic Datasets to Delineate MAIT Cell Roles and Phenotypic Characteristics in Human Malignancies.Frontiers in immunology · 2020Article
- Regulatory T cells induce CD4Cancer immunology, immunotherapy : CII · 2019Article
- Porcine Invariant Natural Killer T Cells: Functional Profiling and Dynamics in Steady State and Viral Infections.Frontiers in immunology · 2019Article
- Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Frontiers in immunology · 2018Review
- Insights Into Mucosal-Associated Invariant T Cell Biology From Studies of Invariant Natural Killer T Cells.Frontiers in immunology · 2018Review
- A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.Central-European journal of immunology · 2017Review
- CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.The Journal of clinical investigation · 2016Article
- Editorial: CD1- and MR1-Restricted T Cells in Antimicrobial Immunity.Frontiers in immunology · 2015Article
- CD1d- and MR1-Restricted T Cells in Sepsis.Frontiers in immunology · 2015Review
- Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Invariant natural killer T cells as sensors and managers of inflammation.Trends in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Invariant natural killer T (iNKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in iNKT cell responses has recently come under scrutiny. Although iNKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current iNKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on iNKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of iNKT cell costimulation and discuss potential treatment modalities based on the responsiveness of iNKT cells to disease-tailored glycolipids and select costimulatory ligands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.